Investor
FT Global Pharmaceutical and Biotechnology Summit
A high-level gathering of life science executives, policymakers, and investors discussing drug development, market access, and commercialization strategies.
- When
- November, Early November
- Where
- London, United KingdomView on Google Maps
- Format
- Hybrid
- Organiser
- Financial Times
- Region
- Europe
- Scale
- About 500 attendees
- Founded
- 2001
The Signal
Organized by the Financial Times, this summit is a premium event focusing on the strategic and financial trends shaping the life sciences. It features interviews with pharmaceutical chief executives, biotechnology founders, regulatory leaders, and investment partners. Key topics include therapeutic pipelines, drug pricing policies, geopolitical challenges, and the integration of digital tools in clinical trials. For healthtech and biotech operators, the summit provides executive perspectives on commercialization, market access, and strategic partnerships.
What to expect
- Strategic discussions on pharmaceutical pipelines and drug pricing models
- Analyses of macroeconomic conditions affecting biotech investment and IPOs
- Debates on artificial intelligence application in drug discovery and development
Who is in the room
Pharmaceutical executives, biotechnology founders, healthcare investors, policymakers, and life sciences consultants attend the event in London.
Background
The summit has run for over two decades, establishing itself as a premier European event for biopharma executives and financial leaders. It has transitioned to a hybrid format, broadening its global reach and integrating digital health technology discussions into its core agenda.
Related events
Running this event, or spotted something out of date?